Jooryung Huh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3424255/publications.pdf

Version: 2024-02-01

136 papers	2,337 citations	218677 26 h-index	276875 41 g-index
139 all docs	139 docs citations	139 times ranked	3964 citing authors

#	Article	IF	Citations
1	A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum Î²-2 Microglobulin to PINK. Cancer Research and Treatment, 2023, 55, 314-324.	3.0	3
2	BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. Modern Pathology, 2022, 35, 480-488.	5.5	6
3	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer Journal, 2022, 12, 25.	6.2	7
4	A prognostic index for extranodal marginalâ€zone lymphoma based on the mucosaâ€associated lymphoid tissue International Prognostic Index and serum Î²2â€microglobulin levels. British Journal of Haematology, 2021, 193, 307-315.	2.5	4
5	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Molecular Cancer Research, 2021, 19, 249-260.	3.4	20
6	Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study. Cancer Research and Treatment, 2021, 53, 270-278.	3.0	1
7	Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disordersâ€“diffuse large B-cell lymphoma. Scientific Reports, 2021, 11, 2880.	3.3	5
8	The limited role of comprehensive staging workâ€up in ocular adnexal extranodal marginal zone lymphoma of mucosaâ€associated lymphoid tissue type (MALToma) with excellent prognosis. British Journal of Haematology, 2021, 193, 848-851.	2.5	4
9	Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intentâ€“based analysis. Blood Advances, 2021, 5, 2142-2152.	5.2	23
10	Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum Î²2-microglobulin Levels. Cancer Research and Treatment, 2021, 53, 847-856.	3.0	9
11	Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Advances, 2021, 5, 3919-3930.	5.2	26
12	Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution. Journal of Pathology and Translational Medicine, 2021, 55, 330-337.	1.1	5
13	Prognostic significance of serum Î²2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified. Leukemia and Lymphoma, 2021, , 1-7.	1.3	4
14	Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms. Blood, 2021, 138, 2395-2395.	1.4	1
15	Identification of microRNAs modulated by DNA hypomethylating drugs in extranodal NK/T-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 66-74.	1.3	9
16	The First Korean Case of Epstein-Barr Virus-positive Natural Killer/T-cell Lymphoma That Progressed From Severe Mosquito Bite Allergy, With Coexistence of Hemophagocytic Lymphohistiocytosis. Annals of Laboratory Medicine, 2020, 40, 80-83.	2.5	2
17	JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma. Annals of Laboratory Medicine, 2020, 40, 1-6.	2.5	0
18	Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP. Leukemia and Lymphoma, 2020, 61, 1119-1125.	1.3	5

#	Article	IF	Citations
19	Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities. Modern Pathology, 2020, 33, 834-845.	5.5	16
20	Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma. Frontiers in Oncology, 2020, 10, 594692.	2.8	8
21	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Advances, 2020, 4, 3391-3404.	5.2	22
22	Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09). Annals of Hematology, 2020, 99, 2831-2836.	1.8	3
23	Clinicopathological and prognostic significance of BCL2, BCL6, MYC, and IRF4 copy number gains and translocations in follicular lymphoma: a study by FISH analysis. Leukemia and Lymphoma, 2020, 61, 3342-3350.	1.3	2
24	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. Journal of Hematology and Oncology, 2020, 13, 148.	17.0	27
25	Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2. Scientific Reports, 2020, 10, 10680.	3.3	5
26	Risk Stratification Using Multivariable Fractional Polynomials in Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2020, 10, 329.	2.8	8
27	The clinical outcomes of rituximab biosimilar CT-P10 (Truxima^{Â®}) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience. Leukemia and Lymphoma, 2020, 61, 1575-1583.	1.3	17
28	Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30â€“Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. Cancer Research and Treatment, 2020, 52, 374-387.	3.0	26
29	Follicular lymphoma with prominent Dutcher body formation after liver transplantation. Blood Research, 2019, 54, 84-84.	1.3	0
30	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer, 2019, 19, 1080.	2.6	17
31	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
32	Classification of malignant lymphoma subtypes in Korean patients: a report of the 4th nationwide study. Journal of Hematopathology, 2019, 12, 173-181.	0.4	9
33	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Modern Pathology, 2019, 32, 741-754.	5.5	39
34	Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis. International Journal of Hematology, 2019, 110, 86-94.	1.6	19
35	Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. Annals of Hematology, 2019, 98, 1657-1664.	1.8	10
36	Beta-2 microglobulin as a prognostic factor of primary central nervous system lymphoma. Blood Research, 2019, 54, 285-288.	1.3	5

#	Article	IF	Citations
37	Multistaining Optimization for Epstein-Barr Virusâ€“Encoded RNA In Situ Hybridization and Immunohistochemistry of Formalin-Fixed Paraffin-Embedded Tissues Using an Automated Immunostainer. Journal of Pathology and Translational Medicine, 2019, 53, 317-326.	1.1	5
38	Complete metabolic response (CMR) in positron emission tomographyâ€“computed tomography (PETâ€CT) scans may have prognostic significance in patients with marginal zone lymphomas (MZL). Hematological Oncology, 2018, 36, 56-61.	1.7	6
39	Epsteinâ€Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma. Hematological Oncology, 2018, 36, 182-188.	1.7	18
40	Endoscopic features and clinical outcomes of colorectal mucosa-associated lymphoid tissue lymphoma. Gastrointestinal Endoscopy, 2018, 87, 529-539.	1.0	28
41	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. Annals of Hematology, 2018, 97, 2363-2372.	1.8	13
42	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia, 2018, 20, 574-593.	5.3	64
43	Central Nervous System Relapse in Patients with Peripheral T-Cell Lymphoma. Blood, 2018, 132, 5346-5346.	1.4	1
44	Prognostic Value of Serum Beta-2 Microglobulin during and after Completing Chemotherapy in Marginal Zone Lymphoma. Blood, 2018, 132, 5335-5335.	1.4	0
45	Central Nervous System Relapse in Patients with Extranodal NK/T-Cell Lymphoma, Nasal Type. Blood, 2018, 132, 1634-1634.	1.4	0
46	RGS1 expression is associated with poor prognosis in multiple myeloma. Journal of Clinical Pathology, 2017, 70, 202-207.	2.0	27
47	PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma. Annals of Hematology, 2017, 96, 1883-1890.	1.8	37
48	Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. Annals of Hematology, 2017, 96, 1509-1515.	1.8	15
49	Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients. Blood Research, 2017, 52, 125.	1.3	7
50	Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma. Blood Research, 2017, 52, 270.	1.3	6
51	Blastic plasmacytoid dendritic cell neoplasm in the CSF. Blood Research, 2017, 52, 158.	1.3	0
52	Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis. Blood Research, 2017, 52, 221.	1.3	4
53	Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. Blood Research, 2017, 52, 285.	1.3	19
54	Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). Oncotarget, 2017, 8, 13367-13374.	1.8	6

#	Article	IF	Citations
55	The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget, 2017, 8, 58122-58132.	1.8	13
56	An isolated cardiac relapse after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia. Korean Journal of Internal Medicine, 2017, 32, 753-757.	1.7	8
57	GLUT1 as a Prognostic Factor for Classical Hodgkinâ€™s Lymphoma: Correlation with PD-L1 and PD-L2 Expression. Journal of Pathology and Translational Medicine, 2017, 51, 152-158.	1.1	20
58	Epstein-Barr Virusâ€“Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification. Journal of Pathology and Translational Medicine, 2017, 51, 352-358.	1.1	67
59	Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives. Journal of Pathology and Translational Medicine, 2017, 51, 224-241.	1.1	12
60	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget, 2016, 7, 76934-76943.	1.8	33
61	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget, 2016, 7, 2401-2416.	1.8	93
62	Genomic Profile of Chronic Lymphocytic Leukemia in Korea Identified by Targeted Sequencing. PLoS ONE, 2016, 11, e0167641.	2.5	27
63	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood, 2016, 128, 3083-3100.	1.4	59
64	Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2016, 22, 3593-3605.	7.0	48
65	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. Tumor Biology, 2016, 37, 7507-7514.	1.8	40
66	A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy. Annals of Hematology, 2016, 95, 1249-1258.	1.8	13
67	Recurrence patterns of mucose-associated lymphoid tissue lymphoma after definitive radiation treatment: A single center experience. Hematology, 2016, 21, 542-548.	1.5	5
68	Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. Hematological Oncology, 2016, 34, 22-27.	1.7	25
69	MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma. Histopathology, 2016, 68, 442-449.	2.9	34
70	Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma. Annals of Hematology, 2016, 95, 801-808.	1.8	18
71	Cutaneous anaplastic large-cell lymphoma (ALCL): A comparative clinical feature and survival outcome analysis of 52 cases according to primary tumor site. Journal of the American Academy of Dermatology, 2016, 74, 1135-1143.	1.2	18
72	Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide Conditioning in Patients with Primary Central Nervous System Lymphoma: A Remarkable Outcome Form Single-Center Experience. Blood, 2016, 128, 3462-3462.	1.4	1

#	Article	IF	Citations
73	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging, 2016, 8, 345-365.	3.1	19
74	RelA NF-Î²B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging, 2016, 8, 3321-3340.	3.1	29
75	Primary Follicular Lymphoma of the Duodenum: A Case Report. Journal of Pathology and Translational Medicine, 2016, 50, 479-481.	1.1	3
76	Insulinâ€like growth factorâ€1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with <scp>MET</scp> expression. International Journal of Experimental Pathology, 2015, 96, 232-239.	1.3	4
77	Splenic rupture in primary amyloidosis with chronic neutrophilic leukemia. Blood Research, 2015, 50, 5.	1.3	1
78	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 5597-5614.	1.8	61
79	The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60â€‰years of age. Hematological Oncology, 2015, 33, 133-140.	1.7	16
80	<scp>TCL</scp>1 expression predicts overall survival in patients with mantle cell lymphoma. European Journal of Haematology, 2015, 95, 583-594.	2.2	8
81	Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. Leukemia and Lymphoma, 2015, 56, 2630-2636.	1.3	11
82	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2015, 28, 1555-1573.	5.5	48
83	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Modern Pathology, 2015, 28, 1297-1314.	5.5	21
84	Evaluation of NF-Î²B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Modern Pathology, 2015, 28, 1202-1213.	5.5	17
85	¹⁸F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in¹⁸F-FDG avidity according to site involvement. Leukemia and Lymphoma, 2015, 56, 3288-3294.	1.3	36
86	Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget, 2015, 6, 5615-5633.	1.8	72
87	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 23157-23180.	1.8	35
88	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. Oncotarget, 2015, 6, 13933-13945.	1.8	33
89	TdT+ T-Lymphoblastic Proliferation in Castleman Disease. Journal of Pathology and Translational Medicine, 2015, 49, 1-4.	1.1	13
90	Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient. Cancer Research and Treatment, 2015, 47, 539-543.	3.0	3

#	Article	IF	Citations
91	Ureteral Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Chronic Inflammation, and Renal Artery Atherosclerosis. Journal of Pathology and Translational Medicine, 2015, 49, 339-342.	1.1	1
92	CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma. PLoS ONE, 2014, 9, e87066.	2.5	46
93	Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems. Journal of Korean Medical Science, 2014, 29, 53.	2.5	26
94	Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience. Blood Research, 2014, 49, 253.	1.3	26
95	Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience. Blood Research, 2014, 49, 170.	1.3	14
96	Reed-Sternberg-like cells in follicular lymphoma. Blood Research, 2014, 49, 147.	1.3	4
97	Primary mediastinal large B-cell lymphoma: a single-center experience in Korea. Blood Research, 2014, 49, 36.	1.3	3
98	Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection. Blood Research, 2014, 49, 115.	1.3	3
99	Current Concepts in Primary Effusion Lymphoma and Other Effusion-Based Lymphomas. Korean Journal of Pathology, 2014, 48, 81.	1.3	36
100	A Case of Type II Enteropathy-Associated T-Cell Lymphoma with Epstein-Barr Virus Positivity. Korean Journal of Pathology, 2014, 48, 426-429.	1.3	6
101	LGALS3 as a prognostic factor for classical Hodgkinâ€™s lymphoma. Modern Pathology, 2014, 27, 1338-1344.	5.5	16
102	Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases. Korean Journal of Pathology, 2014, 48, 209.	1.3	9
103	Cutaneous extranodal natural killer/T-cell lymphoma:ÂA comparative clinicohistopathologic andÂsurvival outcome analysis of 45 cases according toÂthe primary tumor site. Journal of the American Academy of Dermatology, 2014, 70, 1002-1009.	1.2	44
104	Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2014, 20, 5113-5123.	7.0	60
105	18F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase. Nuclear Medicine and Molecular Imaging, 2013, 47, 249-256.	1.0	10
106	Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma. Korean Journal of Pathology, 2013, 47, 526.	1.3	27
107	Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma. Blood Research, 2013, 48, 266.	1.3	16
108	STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 365-365.	1.4	1

#	Article	IF	Citations
109	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 213-213.	1.4	0
110	Prognostic Impact Of Beta-2 Microglobulin In Patients With Non-Gastric Marginal Zone Lymphoma. Blood, 2013, 122, 4297-4297.	1.4	0
111	EBV-associated T and NK cell lymphoproliferative disorders: consensus report of the 4th Asian Hematopathology Workshop. Journal of Hematopathology, 2012, 5, 319-324.	0.4	14
112	Epidemiologic overview of malignant lymphoma. The Korean Journal of Hematology, 2012, 47, 92.	0.7	95
113	Clinical Significance of Immunoglobulin Isotype Switching in Patients with Multiple Myeloma. Blood, 2012, 120, 4980-4980.	1.4	0
114	Prognostic Value of Positron Emission Tomography- Computed Tomography in Patients with Marginal Zone Lymphoma. Blood, 2012, 120, 5084-5084.	1.4	1
115	WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study. Korean Journal of Pathology, 2011, 45, 254.	1.3	68
116	Associations of Methylene Tetrahydrofolate Reductase Polymorphism and Methotrexate-Related Toxicities in Korean Treated for Malignant Lymphoma. Blood, 2011, 118, 1607-1607.	1.4	0
117	Distribution of lymphoid neoplasms in the Republic of Korea: Analysis of 5318 cases according to the World Health Organization classification. American Journal of Hematology, 2010, 85, 760-764.	4.1	109
118	The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study.. Blood, 2010, 116, 1791-1791.	1.4	2
119	PROGNOSTIC SIGNIFICANCE of CD68 EXPRESSION for Korean PATIENTS with HODGKIN'S LYMPHOMA. Blood, 2010, 116, 3888-3888.	1.4	1
120	Primary Mediastinal Large B-Cell Lymphoma: A Single Center Experience in Korea.. Blood, 2009, 114, 5013-5013.	1.4	0
121	SIGNIFICANCE of ABSOLUTE LYMPHOCYTE COUNT at RELAPSE as a PROGNOSTIC FACTOR in PATIENTS with T-CELL NON-HODGKIN'S LYMPHOMA.. Blood, 2009, 114, 2939-2939.	1.4	0
122	VPDL Chemotherapy for T-cell Lymphoblastic Lymphoma (T-LBL) in Adults: Comparison with Upfront Autologous Stem Cell Transplantation in a Single Center. The Korean Journal of Hematology, 2008, 43, 138.	0.7	2
123	Immunohistochemical Prognostic Marker for Diffuse Large B Cell Lymphoma in Patients Treated with CHOP Like Chemotherapy: Validation of the Algorithm by Hans Et Al. and Analysis of Individual Markers. Blood, 2008, 112, 5274-5274.	1.4	0
124	Central Nervous System (CNS) Relapse in Extranodal NK/T Cell Lymphoma, Nasal Type: When Do We Need CNS Prophylaxis in Patients with Extranodal NK/T Cell Lymphoma?. Blood, 2008, 112, 2833-2833.	1.4	0
125	A Phase I Trial of Bortezomib Plus CHOP Every 2 Weeks in Patients with Advanced Stage Diffuse Large B-Cell Lymphomas.. Blood, 2007, 110, 4446-4446.	1.4	2
126	Primary Systemic Anaplastic Large Cell Lymphoma in Korean Adults; Retrospective Analysis of 36 Patients.. Blood, 2006, 108, 4633-4633.	1.4	0

#	Article	IF	Citations
127	Burkittâ€™s Lymphoma in Korea: Clinical Manifestations and Efficacy of Modified CALGB 9251 Regimen (BNHL).. Blood, 2005, 106, 4661-4661.	1.4	2
128	BEAC or BEAM Chemotherapy Followed by Autologous Stem Cell Transplantation in Non-Hodgkinâ€™s Lymphoma Patients: Comparative Analysis on Efficacy and Toxicity.. Blood, 2005, 106, 5291-5291.	1.4	0
129	Relationship between endometrial estrogen and progesterone receptors, and sonographic endometrial appearance in the preovulatory phase. Journal of Obstetrics and Gynaecology Research, 2002, 28, 233-235.	1.3	0
130	Relationship between Endometrial Estrogen and Progesterone Receptors, and Sonographic Endometrial Appearance in the Preovulatory Phase. Journal of Obstetrics and Gynaecology Research, 2000, 26, 95-101.	1.3	6
131	Congenital CD34-positive granular cell dendrocytosis. Journal of Cutaneous Pathology, 1999, 26, 253-258.	1.3	15
132	Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma. American Journal of Hematology, 1999, 60, 205-214.	4.1	48
133	Diagnostic Pitfalls of Merkel Cell Carcinoma and Dramatic Response to Chemotherapy. Journal of Dermatology, 1998, 25, 322-328.	1.2	9
134	The Brenner Tumors of The Ovary: A Clinicopathologic Study. Korean Journal of Gynecologic Oncology and Colposcopy, 1998, 9, 168.	0.0	0
135	Immunohistochemical Study for Expression of p53, bcl-2 and Bax in Uterine Sarcoma. Korean Journal of Gynecologic Oncology and Colposcopy, 1997, 8, 395.	0.0	0
136	Tumor implantation along abdominal trocar site after pelviscopic removal of malignant ovarian tumor: a case report. Journal of Korean Medical Science, 1996, 11, 440.	2.5	6